{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T22:38:38Z","timestamp":1784846318899,"version":"3.55.0"},"reference-count":23,"publisher":"Japanese Society of Internal Medicine","issue":"17","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2015]]},"DOI":"10.2169\/internalmedicine.54.4582","type":"journal-article","created":{"date-parts":[[2015,8,31]],"date-time":"2015-08-31T22:09:57Z","timestamp":1441058997000},"page":"2255-2259","source":"Crossref","is-referenced-by-count":8,"title":["Successful Treatment of Lupus Cerebrovascular Disease with Mycophenolate Mofetil"],"prefix":"10.2169","volume":"54","author":[{"given":"Kazuhiko","family":"Higashioka","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Matsuyama Red Cross Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Matsuyama Red Cross Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Oryoji","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Matsuyama Red Cross Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Kamada","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Matsuyama Red Cross Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Mizuki","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Matsuyama Red Cross Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Tsukamoto","sequence":"additional","affiliation":[{"name":"Department of Medicine and Biosystemic Science, Graduate School of Medical Science, Kyushu University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eisuke","family":"Yokota","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Matsuyama Red Cross Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Akashi","sequence":"additional","affiliation":[{"name":"Department of Medicine and Biosystemic Science, Graduate School of Medical Science, Kyushu University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. American College of Rheumatology Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 42: 599-608, 1999.","DOI":"10.1002\/1529-0131(199904)42:4<599::AID-ANR2>3.0.CO;2-F"},{"key":"2","unstructured":"2. Hanly JG, Walsh NMG, Sangalang V. Brain pathology in systemic lupus erythematosus. J Rheumatol 19: 732-741, 1992."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Barile-Fabris L, Ariza-Andraca R, Olguin-Ortega L, et al. Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann Rheum Dis 64: 620-625, 2005.","DOI":"10.1136\/ard.2004.025528"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Kizu H, Dobashi H, Kameda T, Susaki K, Ishida T. Improvement of irregularity of brain vessel walls in systemic lupus erythematosus by tacrolimus. Clin Rheumatol 30: 715-718, 2011.","DOI":"10.1007\/s10067-010-1591-3"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Futrell N, Millikan C. Frequency, etiology, and prevention of stroke in patients with systemic lupus erythematosus. Stroke 20: 583-591, 1989.","DOI":"10.1161\/01.STR.20.5.583"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Bertsias GK, Ioannidis JPA, Aringer M, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis 69: 2074-2082, 2010.","DOI":"10.1136\/ard.2010.130476"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Hirohata S, Kanai Y, Mitsuo A, Tokano Y, Hashimoto H. Accuracy of cerebrospinal fluid IL-6 testing for diagnosis of lupus psychosis. A multicenter retrospective study. Clin Rheumatol 28: 1319-1323, 2009.","DOI":"10.1007\/s10067-009-1226-8"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Govoni M, Bombardieri S, Bortoluzzi A, et al. Factors and comorbidities associated with first neuropsychiatric event in systemic lupus erythematosus: does a risk profile exist? A large multicenter retrospective cross-sectional study on 959 patients. Rheumatology 51: 157-168, 2012.","DOI":"10.1093\/rheumatology\/ker310"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Rizos T, Siegelin M, Hahnel S, Storch-Hagenlocher B, Hug A. Fulminant onset of cerebral immunocomplex vasculitis as first manifestation of neuropsychiatric systemic lupus erythematosus. Lupus 18: 361-363, 2009.","DOI":"10.1177\/0961203308097448"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Joseph FG, Lammie GA, Scolding NJ. CNS lupus a study of 41 patients. Neurology 69: 644-654, 2007.","DOI":"10.1212\/01.wnl.0000267320.48939.d0"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Efthimiou P, Blanco M. Pathogenesis of neuropsychiatric systemic lupus erythematosus and potential biomarkers. Mod Rheumatol 19: 457-468, 2009.","DOI":"10.3109\/s10165-009-0198-5"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Colasanti T, Delunardo F, Margutti P, et al. Autoantibodies involved in neuropsychiatric manifestations associated with systemic lupus erythematosus. J Neuroimmunol 212: 3-9, 2012.","DOI":"10.1016\/j.jneuroim.2009.05.003"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Mikdashi J, Handwerger B. Predictors of neuropsychiatric damage in systemic lupus erythematosus: data from the Maryland lupus cohort. Rheumatology 43: 1555-1560, 2004.","DOI":"10.1093\/rheumatology\/keh384"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Shimojima Y, Matsuda M, Gono T, Ishii W, Ikeda S. Relationship between clinical factors and neuropsychiatric manifestations in systemic lupus erythematosus. Clin Rheumatol 24: 469-475, 2005.","DOI":"10.1007\/s10067-004-1060-y"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Calabrese LH, Dodick DW, Schwedt TJ, Singhal AB. Narrative review; reversible cerebral vasoconstriction syndromes. Ann Inter Med 146: 34-44, 2007.","DOI":"10.7326\/0003-4819-146-1-200701020-00007"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Sayegh J, Marc G, Augusto JF, Caroff J, Subra JF, Besson V. Reversible cerebral vasoconstriction syndrome in a female patient with systemic lupus erythematosus. Rheumatology 49: 1993-1994, 2010.","DOI":"10.1093\/rheumatology\/keq161"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Fernandes Moca Trevisani V, Castro AA, Ferreira Neves Neto J, Atallah AN. Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus. Cochrane Database Syst Rev 2: CD002265, 2013.","DOI":"10.1002\/14651858.CD002265.pub3"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Stojanovich L, Stojanovich R, Kostich V, Dzjolich E. Neuropsychiatric lupus favourable response to low dose i.v. cyclophosphamide and prednisolone. Lupus 12: 3, 2003.","DOI":"10.1191\/0961203303lu251oa"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Allison AC, Eugui EM. Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil. Immunol Rev 136: 5-28, 1993.","DOI":"10.1111\/j.1600-065X.1993.tb00652.x"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Natsumeda Y, Carr SF. Human type I and II IMPDH as drug targets. Ann NY Acad Sci 696: 88-93, 1993.","DOI":"10.1111\/j.1749-6632.1993.tb17144.x"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Karim MY, Alba P, Cuadrado MJ, et al. Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents. Rheumatology 41: 876-882, 2002.","DOI":"10.1093\/rheumatology\/41.8.876"},{"key":"22","unstructured":"22. Tomietto P, D'Agostini S, Annese V, De Vita S, Ferraccioli G. Mycophenolate mofetil and intravenous dexamethasone in the treatment of persistent lupus myelitis. J Rheumatol 34: 588-591, 2007."},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Jose J, Paulose BK, Vasuki Z, Danda D. Mycophenolate mofetil in neuropsychiatric systemic lupus erythematosus. Indian J Med Sci 59: 353-356, 2005.","DOI":"10.4103\/0019-5359.16652"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/54\/17\/54_54.4582\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T18:40:07Z","timestamp":1498243207000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/54\/17\/54_54.4582\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":23,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.54.4582","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015]]}}}